Search for stock quotes, financial statistics and more
Following a notable acquisition, RBC analyst Douglas Miehm has raised his price target on Knight The... Read More
Following the company’s fourth quarter results, Raymond James analyst Rahul Sarugaser has main... Read More
Raymond James analyst Rahul Sarugaser is feeling GUD about Knight Therapeutics (Knight Therapeutics ... Read More
Despite strong first quarter results, the growth runway for Canadian specialty pharma company Knight... Read More
Raymond James analyst David Novak is slightly clipping his estimate of Knight Therapeutics (Knight T... Read More
Share
Tweet
pin
Share